参考文献/References:
[1] Toh C K, Ong W S, Lim W T, et al.A decade of never-smokers among lung cancer patients-increasing trend and improved survival[J]. Clin Lung Cancer,2018,19(5):e539-e550.
[2] Socinski M A, Obasaju C, Gandara D, et al.Current and emergent therapy options for advanced squamous cell lung cancer[J]. J Thorac Oncol,2018,13(2):165-183.
[3] Sacco P C, Maione P, Palazzolo G, et al.Treatment of advanced non-small cell lung cancer in the elderly[J]. Expert Rev Respir Med,2018,12(9):783-792.
[4] Choi J H, Choi J, Chung S M, et al.The clinical efficacy and safety of four-weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma[J]. Tuberc Respir Dis(Seoul),2018,81(3):219-225.
[5] Yardley D A.nab-Paclitaxel mechanisms of action and delivery[J]. J Control Release,2013,170(3):365-372.
[6] Socinski M A, Bondarenko I, Karaseva N A, et al.Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase Ⅲ trial[J]. J Clin Oncol,2012,30(17):2055-2062.
[7] Gridelli C, Chen T, Ko A, et al.nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase Ⅲ trial[J]. Drug Des Devel Ther,2018,12:1445-1451.
[8] Quoix E, Zalcman G, Oster J P, et al.Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial[J]. Lancet,2011,378(9796):1079-1088.
[9] Sederholm C, Hillerdal G, Lamberg K, et al.Phase Ⅲ trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group[J]. J Clin Oncol,2005,23(33):8380-8388.
[10] Mok T, Wu Y L, Kudaba I, et al.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet,2019,393(10183):1819-1830.
[11] Paz-Ares L, Luft A, Vicente D, et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med,2018,379(21):2040-2051.
相似文献/References:
[1]方剑锋.三联疗法两种疗程治疗老年幽门螺杆菌阳性消化性溃疡患者疗效分析[J].福建医药杂志,2017,39(4):122.
[2]潘金兴 姜锋.老年2型糖尿病患者血清CA199水平及其与血糖的相关性[J].福建医药杂志,2017,39(5):119.
[3]林增钰,袁 音,黄 峰,等.社区老年人空巢状态与营养不良风险的相关性研究[J].福建医药杂志,2021,43(05):19.
LIN Zengyu,YUAN Yin,HUANG Feng,et al.Association between empty-nest status and malnutrition risk among community-dwelling elderly population[J].FUJIAN MEDICAL JOURNAL,2021,43(01):19.
[4]林燕玲,叶静,黄淑玲,等.血清VEGF、BDNF水平与老年糖尿病大鼠认知功能障碍相关性研究[J].福建医药杂志,2022,44(02):123.
LIN Yanling,YE Jing,HUANG Shuling,et al.The correlation between serum levels of VEGF and BDNF and cognitive dysfunction in elderly diabetic rats[J].FUJIAN MEDICAL JOURNAL,2022,44(01):123.
[5]庄宸麟,余惠珍陈毓岱,孙嘉峰,等.控制营养状态评分与老年慢性心衰急性发作患者死亡预后的相关性研究[J].福建医药杂志,2023,45(02):16.
ZHUANG Chenlin,YU Huizhen,CHEN Yudai,et al.Study on the correlation between controlling nutritional status score and death prognosis in elderly patients with acute episode of chronic heart failure[J].FUJIAN MEDICAL JOURNAL,2023,45(01):16.
[6]连学辉,肖红利,杨明,等.老年胸腰椎骨折60例术后炎症反应与疼痛关系分析[J].福建医药杂志,2023,45(02):25.